𧡠*** The researchers found no evidence of a difference in response in biochemical markers of #inflammation between patients with #MIS-C/PIMS-TS who were treated with #IVIG, #steroids, or #biologics, compared with those who were not.
*** Despite a lack of evidence, π¬π§ and πΊπΈ treatment guidelines for MIS-C/PIMS-TS have become very similar.
*** By the end of the study period, most patients had received immunomodulation.
#AcademicChatter #AcademicTwitter #MedTwitter #foamed #MedStudentTwitter #LongCovidKids
*** By the end of the study period, most patients had received immunomodulation.
#AcademicChatter #AcademicTwitter #MedTwitter #foamed #MedStudentTwitter #LongCovidKids
*** The 12 patients who did not receive any immunomodulators had similar decrease in inflammatory markers as those treated.
*** Of the 14 guidelines analyzed, the use of IV #immunoglobulin, #steroids, and #biologics was universally recommended.
*** Of the 14 guidelines analyzed, the use of IV #immunoglobulin, #steroids, and #biologics was universally recommended.
*** Clinicians treating MIS-C/PIMS-TS should retain equipoise and participate in clinical trials of treatments currently being used for this important condition. @iapindia @ProfSomashekhar @naveenthacker @EricTopol
β’ β’ β’
Missing some Tweet in this thread? You can try to
force a refresh
γ
